Mhedzisiro Inoshamisa yeKurapwa kweCAR-T Yakatarirwa neCD7 yeT-ALL neT-LBL
Kuedzwa kwekiriniki munguva pfupi yapfuura kwakaratidza kufambira mberi kukuru mukurapa kweT-cell acute lymphoblastic leukemia (T-ALL) yakadzoka kana kuti isingashande uye T-cell lymphoblastic lymphoma (T-LBL) uchishandisa CD7-targetted chimeric antigen receptor (CAR) T cell therapy. Chidzidzo ichi, chakaitwa nechikwata cheHebei Yanda Lu Daopei Hospital neLu Daopei Institute of Hematology, chaisanganisira varwere makumi matanhatu vakagamuchira dosi imwe chete yemasero eT anti-CD7 CAR (NS7CAR) T akasarudzwa nenzira yechisikigo.
Mhedzisiro yekuyedza inokurudzira zvikuru. Pakazosvika zuva rechi28, 94.4% yevarwere vakawana deep complete remission (CR) mu bone morrow. Pamusoro pezvo, pakati pevarwere makumi matatu nevaviri vane chirwere che extramedullary, 78.1% vakaratidza mhinduro yakanaka, 56.3% vachiwana complete remission uye 21.9% vachiwana partial remission. Mwero wekurarama kwemakore maviri uye wekurarama usina progressive waive 63.5% uye 53.7%, zvichiteerana.
Kurapa uku kutsva kunozivikanwa nekuchengetedzeka kwayo, ne cytokine release syndrome inowanikwa mu91.7% yevarwere (vazhinji vegiredhi 1/2), uye kukuvadza kwetsinga muuropi kwakaonekwa mu5% yezviitiko. Uyezve, chidzidzo ichi chakawana kuti varwere vakaramba vachiisirwa ma "consolidation transplants" mushure mekuwana CR vaive nehuwandu hwakakura hwekurarama vasina kufambira mberi kana tichienzanisa nevaya vasina.
Kambani yedu iri kutsvagawo mukana wekurapa neCD7 CAR-T cell therapy nechinhu chayo, nechinangwa chekubatsira mukusimudzira kurapwa kwekenza yeT-cell.
Zvakawanikwa izvi zvinoratidza mukana wekurapa nemasero eCAR-T anoshandiswa neCD7 kupa tariro itsva kune varwere vane T-ALL neT-LBL vasingachagoni kurapwa kana kuti vakadzokera kuzvirwere, zvichiratidza danho guru mukurwisa zvirwere izvi zvinonetsa.